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A B S T R A C T
Ever since British Physician William Withering first described the use of foxglove extract for treatment of pa-
tients with congestive heart failure in 1785, cardiotonic steroids have been used clinically to treat heart failure
and more recently atrial fibrillation. Due to their ability to bind and inhibit the ubiquitous transport enzyme
sodium potassium pump, thus regulating intracellular Na+ concentration in every living cell, they are also an
essential tool for research into the sodium potassium pump structure and function. Exogenous CTS have been
clearly demonstrated to affect cardiovascular system through modulation of vagal tone, cardiac contraction (via
ionic changes) and altered natriuresis. Reports of a number of endogenous CTS, since the 1980s, have intensified
research into their physiologic and pathophysiologic roles and opened up novel therapeutic targets. Substantive
evidence pointing to the role of endogenous ouabain and marinobufagenin, the two most prominent CTS, in
development of cardiovascular disease has accumulated. Nevertheless, their presence, structure, biosynthesis
pathways and even mechanism of action remain unclear or controversial. In this review the current state-of-the-
art, the controversies and the remaining questions surrounding the role of endogenous cardiotonic steroids in
health and disease are discussed.
1. Introduction
In 1785 William Withering observed that digitalis glycoside beyond
its diuretic effects also "has a power over the motion of the heart with a
degree yet unobserved in any other medicine" [1]. In subsequent years,
it was recognised that digitalis could also stabilise a rapid and irregular
heart-beat [2] and some hundred years later, Fothergill reported that
digitalis also enhanced ventricular contraction [3]. In the 1980s
Hamlyn and colleagues reported the presence of endogenous sodium
potassium pump inhibitors, termed cardiotonic steroids (CTS), in pa-
tients with essential hypertension [4] and healthy controls [5–7]. De-
spite almost four decades of intense research into the role of en-
dogenous CTS in physiology and disease unanswered questions,
heightened discussion and disagreement dominate the research field.
Even the mere existence of endogenous, circulating CTS is questioned!
Further disagreements and questions relate to their structure, biological
target, interaction with digoxin, mechanism of action and function in
health and disease. Digoxin, an archetypal CTS, is still used for treat-
ment of patients with atrial fibrillation and heart failure. Research into
the role of endogenous CTS continues and the clinical use of digoxin,
while reduced, is unlikely to come to a halt. Aim of this review is to
highlight the current state-of-the-art of the endogenous CTS in health
and disease and discuss some of the key questions that remain to be
addressed.
2. Sodium potassium pump is the primary target for CTS
Sodium potassium pump (NKA) is ubiquitous and as such plays a
key role in many physiological processes in the body. NKA uses the free
energy of hydrolysis of ATP to exchange three intracellular Na+ ions for
two extracellular K+ ions, thus setting the electrochemical gradient for
both Na+ and K+ across the cell membrane. NKA is therefore vital for
maintaining the resting potential and Na+ and K+ gradients in almost
every eukaryotic cell. These gradients ensure basic cellular homeostasis
such as regulation of cell volume, essential ionic, glucose and amino
acid transport processes. In excitable cells NKA activity restores the
Na+ and K+ gradients following depolarisation and in the kidney its
activity provides the driving force for Na+ reabsorption essential to
control extracellular volume and blood pressure. Among the many
Na+-dependent transmembrane transport processes in muscle cells, the
activity of the NKA drives Na+/Ca2+ exchanger (NCX) and thus reg-
ulates the concentration of Ca2+ in both the cytosol and the sarco-
plasmic reticulum (SR). Furthermore, recent evidence points towards a
crucial role for the NKA in neurological function [8,9].
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The work of Skou [10] and others on the NKA structure and function
over many years identified that CTS bind to the conserved binding site
and thereby inhibit NKA activity. Commonly referred to as the “ouabain
binding site”, CTS binding site resides within the catalytic domain of
the NKA α subunit [11], see Fig. 1. It is highly conserved across the
species, suggesting an important physiological function. Mutations of
the ouabain binding site, leading to CTS desensitisation, have been
identified in monarch butterflies and leaf beatles that feed on plants
rich in digitalis [12,13]. Similar mutations are also observed in toads,
presumably developed as adaptational protection to high concentra-
tions of CTS in their skin [14]. Remarkably, mice and rats also contain a
CTS insensitive α-1 isoform [15,16]. It is unclear as to the benefits of
this adaptational mutation and further studies are warranted and could
shed light on the physiological and pathophysiological roles of CTS.
NKA is composed of a catalytic α subunit, regulatory β subunit and
an accessory FXYD protein [17,18]. β subunit stabilises the NKA and
helps the complex traffic through the secretory pathway to the plasma
membrane [19,20]. In the heart, FXYD protein named phospholemman
modulates NKA activity in response to kinase/phosphatase mediated
stimuli [18,21–24]. NKA functional unit is made up of α and β mac-
romolecular complex with four α (α1, α2, α3 and α4), three β isoforms
(β1, β2 and β3) [25,26] and a FXYD protein, allowing a formation of a
number of different NKA isozymes with distinct transport and phar-
macological properties [27]. Whether multiple isozyme combinations
exist within the same heart, whether they demarcate distinct chambers
or even distinct topologies within a single cardiomyocyte, is not known
and warrants investigation. It has been clearly demonstrated that CTS
differentially affect alpha subunits, yet little information exists as to the
biological relevance of these (see Pavlovic review [28]). Preliminary
work shows that in the heart and kidneys α1 is the dominant isoform
regulating bulk Na+ whereas α2 plays a more prominent role in smooth
muscle contraction and has been shown to significantly contribute to
regulation of T-tubular Na+ and thus modulation of cardiac contrac-
tion, via its indirect effects on the Na+/Ca2+ exchanger (NCX) [18,29].
Digoxin and ouabain have all been shown to reduce heart rate [30], and
this is likely to be the primary mechanism for beneficial effects ob-
served in patients with atrial fibrillation and heart failure. When
compared to ivabradine, another rate lowering drug, digoxin performed
as well in risk reduction for worsening heart failure [31]. NKA activity
has been demonstrated to play an important role in the brain. Muta-
tions in the brain α1 and α3 NKA isoforms affecting the NKA activity
have been identified and linked with the neuronal defects [8,9]. Whe-
ther CTS-mediated regulation of the brain NKA plays a significant
functional role in neuronal control remains to be determined.
Relevant questions:
What is the relevance of different NKA isoforms in different tis-
sues?
Are the NKA isoforms differentially expressed in different
chambers of the heart?
Why is the CTS binding site not conserved in mice and rats?
What evolutionary advantage does desensitisation of the CTS
binding site confer to mice and rats?
3. Structure and biosynthesis of the endogenous CTS
Whilst the existence of an endogenous, circulating, natriuretic
factor, targeting the NKA may have been suggested as early as 1960s,
Hamlyn and colleagues were the first to demonstrate and identify the
presence of a ouabain-like compound in human plasma [6,7]. Initial
mass spectrometry studies showed the compound to be similar to
ouabain, with adrenals showing 500-fold higher concentrations, pos-
sibly indicating the origins [5]. Development of an immunoassay for
detection of endogenous ouabain [32] allowed multiple studies in
serum of experimental animals and humans. Subnanomolar con-
centrations of ouabain were detected in the blood of patients with es-
sential hypertension [33–35], heart failure [36,37], acute kidney injury
[38–40], and end stage renal failure [41]. Some evidence exists for the
presence of digoxin in human urine [42] and of deglycosylated con-
geners of digoxin in mammals [43,44]. Marinobufagenin was isolated
and identified in urine of patients with myocardial infarction [45] and
serum of patients with terminal renal failure [46]. Structurally related
telocinobufagin, the reduced form of marinobufagenin, was identified
as a constituent of human serum in patients with terminal renal failure
[46], at higher concentration than that of marinobufagenin and oua-
bain. It is likely that other bufadienolides may also be present in
Fig. 1. Structure of the NKA and the che-
mical structures of its commonly described
ligands ouabain, marinobufagenin and di-
goxin. NKA is made up of the α and β subunits
and the accessory FXYD protein. Conserved
CTS binding site is found within the α subunit.
Three commonly studied CTS are shown on the
right. Ouabain and marinobufagenin have
been detected in circulation in patients and
healthy controls. Ouabain and digoxin have a
five-membered lactone ring, whereas mar-
inobufagenin contains a six-membered lactone
ring.
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circulation. Indeed there are reports of proscillaridin A- [47] and bu-
falin-like [48] immunoreactive substances detected in human serum.
Some of the studies have relied on the use of antibody-based ELISA
methods for detection of the endogenous CTS whereas others have used
high-resolution mass spectrometry and NMR, though often without
detailed validation. Baecher et al. have recently developed a validated
ultra-performance liquid chromatography tandem mass spectrometry
(UPLC-MS/MS) method for detection and quantification of ouabain,
with a lower detection limit of 1.7 pmol/L [49]. Controversially, they
found no ouabain in the plasma of 5 control and 25 heart failure pa-
tients and thus concluded that endogenous ouabain detected previously
is an artifact. Disqualifying 30 years of work with a single study in 30
patients, though well executed, seems premature. Unsurprisingly, this
precipitated a flurry of robust exchanges between the interested parties
[50–52] with strong views being expressed on both sides. In their re-
view [53], Hamlyn and Blaustein rightly argue for possible presence of
several isomers of ouabain, and considering detection of several
structurally related CTS, e.g. marinobufagenin, telocinobufagin, de-
glycosylatyed digoxin congeners, it is possible that several CTS species
exist in circulation. No attempts have been made thus far to develop
validated LC-MS/MS methods for detection and quantification of mul-
tiple CTS in plasma or serum. With the recognition that steroids do not
exist nor function in isolation of others, development of methods for
detection of CTS panel is necessary in order to move the field forward.
Biosynthesis pathways for the CTS are unclear, though existing
evidence suggests that CTS are synthesised from cholesterol in the
adrenal glands [54,55] and possibly hypothalamus [56]. Indeed, mis-
sense polymorphism (rs2254524 V642 L) in lanosterol synthase, an
enzyme involved in cholesterol biosynthesis, were shown to affect
ouabain biosynthesis [57]. Can this pathway be targeted pharmacolo-
gically requires investigation. The trigger for biosynthesis initiation
seems complex, with serum concentrations of ouabain and mar-
inobufagenin increasing in response to volume expansion [58], adre-
nocorticotropic hormone, angiotensin II, vasopressin, and pheny-
lephrine [54,59], adding another layer of complexity.
Relevant questions:
Which CTS are present in circulation, if any?
What is the effect of multiple different CTS on cardiac, smooth
muscle, neuronal and kidney function? Do they act synergistically
or is there antagonism?
How do endogenous CTS get synthesised and can these bio-
synthetic pathways be targeted?
4. CTS mechanism of action and interaction with digoxin
Textbook model describes CTS-mediated inhibition of the cardiac
NKA, thereby, raising intracellular Na+ and Ca2+ (via NCX), see Fig. 2.
The effects of acutely increased Ca2+ on contractility [60] are well
described and this is postulated to be the inotropic mechanism pro-
viding improved cardiac output in heart failure patients. Digoxin, and
digitoxin also reduce heart rate, presumably by parasympathomimetic
effects, and as such are used for rate control in patients with atrial fi-
brillation. Of course, it may be that bradycardic effects are the primary
mechanism for improved morbidity in patients with heart failure. It is
unclear, whether the effects on heart rate are mediated directly on the
vagus, sino-atrial node, on cardiac conduction, or possibly on all of
them. Levels required to achieve these effects in patients are around 1
nM. Considering that circulating concentrations of CTS are in the range
of 0.05-0.7 nM [4,5,33,45,46,61–68], it is questioned whether inotropic
and bradycardic effects are likely to be observed. Alternative theory
that does not involve modulation of intracellular Na+ and Ca2+ con-
centrations was presented [69]. This hypothesis proposes that the NKA
acts as a receptor for the CTS and thus plays a signaling role [70],
regulating early response genes associated with cell growth [71]. In this
model, Lie and Xie suggest that a fraction of inactive NKA subunits are
localised in the caveolae and are physically associated with other key
signaling proteins such as EGFR and Src [72,73] see Fig. 2. Binding of
the CTS leads to activation of hypertrophic and fibrotic signaling cas-
cades via NKA-Src-ERK [71]. Evidence also exists for the involvement of
other signaling molecules, phospholipase C, TRP proteins, PI(3)K, and
PKC [69,73–77] and that the CTS induce the endocytosis of the CTS-
NKA-Src-EGFR complex [74–76]. There is disagreement whether the
activation of signaling cascades via CTS indeed occurs independently of
NKA inhibition and the accompanying increases in intracellular Na+
and Ca2+ [78,79]. There is certainly substantive evidence that acute
CTS inotropic effects and activation of NKA-Src-ERK signaling cascades
depend on the presence of functional NCX and intracellular sodium and
calcium increases [60,80,81].
Presence of endogenous CTS raises an important therapeutic query,
if endogenous CTS exist in patients treated with digoxin or digitoxin,
how do these affect outcomes? It is possible that administration of di-
goxin to patients with already raised endogenous CTS can be detri-
mental. Link between mortality and elevated serum levels of CTS in
heart failure patients has been clearly established. Heart failure patients
treated with therapeutic doses of digoxin, where serum levels of digoxin
are> 1.2 ng/ml (as measured by ELISA with poor specificity), are as-
sociated with 11.8 % increase in mortality [82]. Thus, differing levels of
endogenous cardiotonic steroids may partly explain the varied success
of digoxin in this patient population and also the susceptibility to ad-
verse drug reactions and overt toxicity. Surprisingly, experiments in rat
arteries suggest potential antagonism of ouabain and digoxin [83], and
digoxin was shown to oppose ouabain-induced hypertension [84]. This
may explain the beneficial effects of digoxin therapy in heart failure
patients [85], however, whether antagonism between digoxin and
ouabain, and other CTS exists in the heart and what the therapeutic
Fig. 2. Schematic diagram of ionic versus signaling pathways for cardio-
tonic steroid effects. In the classic pathway (shown on the left), CTS binds and
inhibits the NKA, which in turn is accompanied by changes in cytosolic [Na+].
The increase in cytosolic [Na+] then reduces NCX activity and induces an in-
crease in cytosolic [Ca2+]. High cytosolic [Ca2+] mediates muscle contraction
(inotropy) or activates a variety of signaling pathways. It is unclear whether the
effects of CTS on heart rate (bradycardia) are also mediated via the ionic
pathway. The signaling pathway (shown on the right hand side) occurs in the
caveolar domain and involves the physical interaction with Src. When the CTS
binds the NKA, SRC gets activated inducing further activation of mitogen-ac-
tivated protein kinase (ERK) through activation of its mitogen-activated protein
kinase kinase (MEK).
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implications of these findings are, remains to be investigated.
Relevant questions:
Are the clinical benefits of CTS in heart failure patients primarily
mediated via heart rate reduction?
Do endogenous CTS levels affect response to digoxin therapy
in patients with heart failure and atrial fibrillation?
Does the antagonism between digoxin and endogenous CTS
exist in the heart?
5. Endogenous CTS in physiology and pathophysiology
CTS were shown to be involved in cardiac contraction, heart rate
modulation, blood pressure regulation and natriuresis. Chronic ex-
posure to CTS can lead to remodelling of the heart, kidneys and arterial
walls but also cardiac fibrosis and arrhythmias (Fig. 3). Their secretion
seems to be driven by kidney dysfunction and sodium and volume
status and is likely involved in a number of diseases from uremic car-
diomyopathy, preeclampsia, hypertension, congestive heart failure,
myocardial ischemia-induced arrhythmias and diabetes mellitus.
Regulation of sodium content and thus blood volume is proposed as
the primary physiological role of endogenous CTS. The basis of this
natriuretic control is thought to be dependent on the direct inhibition of
the α1 NKA isoform in renal tubular cells [86]. The most convincing
evidence in support of this are the studies by Periyasami and colleagues
where marinobufagenin antibodies given to salt loaded rats lowered
urinary excretion and increased NKA activity [87]. Given, high simi-
larity in chemical structures between different CTS, antibodies raised
against individual CTS tend to have poor specificity [88] and thus
marinobufagenin may not necessarily be the primary modulator. In-
deed, increases in both endogenous ouabain and marinobufagenin are
observed in states of volume expansion and volume expansion mediated
hypertensive syndromes that are related to water and salt accumulation
[62,86,89]. Beyond the expected inhibition of the NKA, administration
of ouabain or marinobufagenin also resulted in translocation of the
NKA to intracellular compartments via clathrin-dependent endocytosis
[76]. This translocation required PI(3)K activation, the plasmalemmal
pump to be in the context of caveola, and signaling through the Src-
EGFR pathway [75]. It is therefore suggested that salt loading leads to
increases in ouabain and marinobufagenin in the proximal tubules,
both of which act to decrease Na+ through NKA inhibition and/or ac-
tivation of a signaling mechanism mediated by NKA-Src-EGFR cascades.
This decrease in renal Na+ reabsorption is expected to lead to an in-
crease in urinary Na+ excretion. In studies of healthy individuals, salt
loading for up to 6 days lead to a transient elevation in plasma ouabain
and sustained increase in marinobufagenin, followed by an increase in
urine Na+ excretion [58,90]. CTS are also implicated in control of
blood pressure and infusion of ouabain or marinobufagenin, at con-
centrations comparable with in vivo plasma levels, lead to an increase in
blood pressure [66,91–93]. Indeed, increased levels of endogenous
ouabain were detected in patients with essential hypertension [33,34]
and preeclampsia [94–96]. Hypertension induced by salt loading,
ouabain infusion or preeclampsia was reduced by immune-neutralisa-
tion with anti-CTS antibodies [97,98] or CTS antagonists rostafuroxin
[99] and resibufogenin [100]. It should be noted however that rosta-
furoxin did not reduce blood pressure in hypertensive patients enrolled
in Ouabain and Adducin for Specific Intervention on Sodium in Hy-
pertension (OASIS-HT) phase-2 Trial [101]. Whilst the evidence for the
role of endogenous CTS in natriuresis and blood pressure homeostasis is
mounting it is unclear which endogenous CTS are involved and whether
the acute and chronic responses are differentially modulated.
Relevant questions:
Do endogenous CTS directly modulate natriuresis and blood
pressure or are they simply by products of these homeostatic
mechanisms?
Are there differences in CTS biosynthesis between the acute
and chronic responses to salt loading?
Which CTS are involved in physiological volume and blood
pressure control?
Endogenous CTS levels were also shown to be increased in animal
models and patients with acute kidney injury [40], chronic kidney
Fig. 3. Graphical representation of the pro-
posed biosynthesis and function of en-
dogenous cardiotonic steroids. Synthesis of
endogenous cardiotonic steroids is thought to
occur in the adrenal cortex from cholesterol.
Acute effects of endogenous cardiotonic ster-
oids are mediated via inhibition of the NKA.
Isoform specific effect in each tissue is shown
in red. Acute and chronic effects of elevated
cardiotonic steroids levels on the specific or-
gans are shown in black boxes. Adapted from
Schoner and Scheiner-Bobis [107].
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disease [66], end stage renal disease [41,46], myocardial infarction
[102] and heart failure [36,103,104]. Most of the studies demonstrate
increases in ouabain and marinobufagenin from circa 0.3 nM in healthy
individuals to circa 0.7–1.0 nM in patients. The evidence in favor of the
hypothesis that endogenous CTS drive the disease progression rather
than simply act as biomarkers of pathology is growing. In healthy adult
rats administration of marinobufagenin for 4 weeks led to increases in
blood pressure, diastolic dysfunction and ventricular hypertrophy
[66,105]. Remarkably, active and passive immunisation against mar-
inobufagenin reversed most of these alterations [66,105]. Independent
studies by Ferrandi et al. showed that infusion of 0.7 nM of ouabain for
18 weeks in healthy adult rats induced hypertension and left ventricular
hypertrophy and could be reversed by ouabain antagonist PST2238
[92]. These studies demonstrate that chronic exposure to pathophy-
siological concentrations in healthy animals can lead to some of the
cardiovascular changes observed in patients, however, utilisation of
animal models with a preserved NKA sensitivity to CTS is required to
provide further mechanistic insights. Whether immunisation for CTS or
intravenous administration of antibodies raised against CTS (e.g. in
patients on renal replacement therapy) is beneficial to these patient
populations is an easily testable and attractive proposition.
Relevant questions:
Which CTS are synthesised in patients with renal and heart
failure?
Is the cardiovascular disease progression mediated by chronic
elevation of CTS?
Does quenching of endogenous CTS by immunisation or ad-
ministration of antibodies against CTS represent a viable ther-
apeutic option for patients with chronically high CTS levels?
6. Conclusion
Administration of CTS was conclusively shown to modulate con-
traction, blood pressure regulation, natriuresis and chronically can
contribute to remodelling of the heart, kidneys and arterial walls.
Although endogenous CTS have been detected in blood of patients with
kidney and cardiovascular dysfunction as early as 1981, the chemical
identities of CTS and mechanistic insight into the cardiovascular phy-
siology and pathogenesis of these molecules remains unclear. Antibody-
based assays cannot distinguish different CTS due to their high struc-
tural similarity. Furthermore there is a clear need for human studies as
murine NKA shows a 1000 fold reduced sensitivity to CTS [106]. A clear
barrier to further expansion of knowledge is our lack of tools to accu-
rately detect and measure the CTS present in circulation and thus
identify patients with a positive CTS status. Understanding how these
endogenous molecules interact with digoxin is also important if we are
to come up with novel stratified therapies, better tailored for treatment
of patients with heart failure and atrial fibrillation. These studies must
be carried out in either human tissue or animal models with preserved
NKA sensitivity to CTS, rather than mice and rats, where NKA sensi-
tivity is reduced.
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